Your session is about to expire
Genvoya vs Descovy
Introduction
For patients living with HIV (Human Immunodeficiency Virus), certain antiretroviral medications can help manage the virus and prevent it from progressing to AIDS. Genvoya and Descovy are two such drugs that are often recommended for treating HIV infection in adults and children who weigh at least 25 kilograms. Both of these medicines contain a combination of antiretrovirals, but they differ slightly in their specific components.
Genvoya contains four different substances: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Descovy on the other hand includes only two active ingredients: emtricitabine and tenofovir alafenamide.
Both Genvoya and Descovy work by inhibiting enzymes required by the virus to replicate itself in human cells, thereby reducing viral load within an individual's body while bolstering immune system function. Choosing between these treatments usually depends on patient-specific factors including current health status, potential side effects tolerance levels or possibly drug-to-drug interaction considerations.
Genvoya vs Descovy Side By Side
| Attribute | Genvoya | Descovy |
|---|---|---|
| Brand Name | Genvoya | Descovy |
| Contraindications | Should not be taken with dofetilide. Not approved for use by individuals who have previously had no antiretroviral therapy or whose HIV infection has been previously treated. | Should not be taken with dofetilide. Not recommended for individuals with unknown or positive HIV-1 status when considering for PrEP. |
| Cost | $3,400 for 30 tablets | $1,800 for 30 tablets |
| Generic Name | Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide | Emtricitabine and tenofovir alafenamide |
| Most Serious Side Effect | Worsening of Hepatitis B infection, kidney problems or kidney failure, lactic acidosis, bone problems, liver problems | Liver problems, kidney problems, lactic acidosis |
| Severe Drug Interactions | Dofetilide | Dofetilide |
| Typical Dose | One tablet orally once a day for adults and children who weigh at least 25 kilograms | One tablet daily for adults and children weighing at least 35 kilograms for HIV-1 treatment. For PrEP in individuals weighing at least 35 kilograms without an existing HIV-1 infection, one tablet taken orally once per day. |
What is Genvoya?
Genvoya and Descovy are both antiretroviral medications primarily used in the management of HIV. Genvoya, which was approved by the FDA in 2015, is a combination pill that contains elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. It effectively inhibits viral replication by blocking key stages of the HIV lifecycle. This medication is prescribed for people who either are starting their first treatment or those replacing another regimen.
Descovy, on the other hand, combines two active ingredients: emtricitabine and tenofovir alafenamide. Approved by the FDA in 2016 as part of an antiretroviral therapy (ART), it differs from Genvoya because it does not contain elvitegravir nor cobicistat but has shown to have fewer possible long-term side effects related to bone density and kidney function due to its more targeted delivery into cells infected with HIV compared to other drugs within this category.
What conditions is Genvoya approved to treat?
Genvoya is approved for the treatment of certain conditions related to HIV:
- Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who weigh at least 25 kg
- As a complete regimen or in combination with other antiretroviral agents for treating people living with HIV.
It should be noted that Genvoya is not approved for use by individuals who have previously had no antiretroviral therapy or whose HIV infection has been previously treated.
How does Genvoya help with these illnesses?
Genvoya and Descovy are both antiretroviral medications used to manage HIV by decreasing the amount of virus in the body. They work by inhibiting enzymes that allow the replication of the virus, thus lowering its load within an individual's system.
In Genvoya's case, it contains four active drugs: elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. Elvitegravir is an integrase inhibitor which blocks one of the proteins needed for a virus to integrate into human DNA, thereby preventing viral replication. Cobicistat boosts elvitegravir levels by reducing its metabolism in liver so that less drug can have a more potent effect over longer periods.
On another hand, Descovy consists only of two components: emtricitabine and tenofovir alafenamide; offering fewer side effects due to lower number of constituents but still effectively manages HIV with daily use.
Both medicines emphasize on maintaining lower amounts of HIV in bloodstream helping patients control their condition while leading healthier lives. However decision between these two should be made considering patient-specific factors like kidney health or bone density as they may be affected differently.
What is Descovy?
Descovy is a brand name for a combination of two antiretroviral medications, emtricitabine and tenofovir alafenamide, used in the treatment and prevention of HIV/AIDS. Similar to Genvoya (which also includes elvitegravir and cobicistat), Descovy works by inhibiting the replication of the virus within T cells. However, unlike Genvoya, Descovy does not include an integrase inhibitor or booster medication.
The FDA first approved Descovy in 2016 due to its effectiveness at lowering viral loads while demonstrating fewer side effects compared to other treatments. Notably, it has less impact on kidney function and bone density than similar drugs like Genvoya - which can be essential considerations for long-term users or those with pre-existing conditions relating to these areas.
It's also important that patients know that while both are effective at managing HIV-1 infections when taken correctly, neither drug provides a cure for HIV or AIDS nor prevent transmission of the virus to others.
What conditions is Descovy approved to treat?
Descovy is a medication approved by the FDA for two main uses:
- As part of HIV-1 treatment in combination with other antiretroviral agents
- Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in adults and adolescents who are at risk.
How does Descovy help with these illnesses?
Descovy is a combination antiretroviral medication used to treat and prevent HIV/AIDS, acting as an inhibitor of reverse transcriptase. This enzyme plays a crucial role in the replication of HIV, so Descovy's action helps to limit viral growth. The combination of active ingredients within Descovy (emtricitabine and tenofovir alafenamide) ensures that it offers robust viral suppression while potentially having less impact on long-term renal and bone health compared to other options like Genvoya. Just like in Wellbutrin’s case where it might be combined with SSRIs when patients do not respond well to typical antidepressants; Descovy may also be combined with other antiretroviral drugs if a patient does not respond effectively enough on their own or based on drug resistance profiles.
How effective are both Genvoya and Descovy?
Both Genvoya and Descovy are antiviral medications used in the treatment of HIV-1 infection, and they were both developed by Gilead Sciences. Their approvals came about 1 year apart with Genvoya being approved by the FDA in 2015 followed by Descovy's approval in 2016. These two regimens, while designed to treat the same condition, have different compositions which may influence their prescription under certain circumstances.
The effectiveness of Genvoya and Descovy was directly compared in a clinical trial where patients who switched from Genvoya to Descovy maintained similar rates of viral suppression but had improved kidney and bone safety markers. This study suggested that both drugs exhibit comparable efficacy when it comes to managing HIV symptoms, however, each presents unique benefits regarding patient tolerance and side effects.
A review showed that Genvoya is highly effective at suppressing viral load within the first few weeks of therapy initiation. Its comprehensive formulation makes it a convenient one-pill-a-day regimen for many patients living with HIV-1 infection regardless of whether they've received prior treatment or not.
On the other hand, studies indicate that Descovy has a better renal and bone safety profile than other TDF-based regimens like Genvoya - making it an attractive option for patients with pre-existing kidney disease or those at risk for osteoporosis. Despite this advantage though, data confirms its efficacy as part of combination therapy rather than standalone use.
In conclusion, although both these options present high levels of efficiency against HIV-1 infection control; choosing between them will often depend on individual patient needs such as co-morbid conditions like renal disease or osteoporosis.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Genvoya typically prescribed?
Dosages for Genvoya and Descovy are both centered around one tablet per day, as they are used in the treatment of HIV. For Genvoya, adults and children who weigh at least 25 kilograms should take one tablet orally once a day. On the other hand, Descovy's dosage varies depending on whether it's being used for HIV-1 infection treatment or pre-exposure prophylaxis (PreP). For treating HIV-1 infection in combination with other antiretroviral drugs, adults and children weighing at least 35 kilograms should take one tablet daily while for PreP in individuals weighing at least 35 kilograms without an existing HIV-1 infection, again the recommended dose is one tablet taken orally once per day. Always consult your healthcare provider before starting either medication to ensure that you're getting the correct dosage.
At what dose is Descovy typically prescribed?
Descovy treatment is typically initiated as a once-daily regimen. Each tablet of Descovy contains 200mg of emtricitabine and 25mg of tenofovir alafenamide, to be taken orally with or without food. Unlike Genvoya, Descovy doesn't have any other drugs in it and can be used in combination with other HIV medications depending on the patient's specific needs. The dose remains consistent at one tablet per day; there is no need for increasing dosage over time unless recommended by your healthcare provider. It's important that patients follow this daily routine consistently, as missing doses can lead to drug resistance and decreased efficacy in managing HIV symptoms.
What are the most common side effects for Genvoya?
Common side effects of Genvoya may include:
- Nausea
- Diarrhea
- Fatigue (general weakness and tiredness)
- Headache
- Abdominal pain, discomfort or bloating
- Dizziness
- Skin rash or itchiness
- Unusual dreams
In contrast, Descovy's common side effects might include:
- Nausea
- Changes in body fat distribution (increased fat on upper back and neck)
- Increased cholesterol levels
- Insomnia (difficulty sleeping)
- Rash or skin discoloration
- Diarrhea
Always remember that these are not exhaustive lists, and if you experience any unusual symptoms while taking either medication, seek medical attention promptly.
Are there any potential serious side effects for Genvoya?
When comparing Genvoya to Descovy, it's crucial to understand the potential side effects of each medication. Despite their efficacy in treating HIV-1 infection, both can cause potentially serious side effects:
- Worsening of Hepatitis B (HBV) infection if you have HBV and stop taking these medicines
- Kidney problems or kidney failure: increased urination, extreme thirstiness, swelling in your limbs or feeling fatigued are symptoms that may indicate this.
- Lactic acidosis: a dangerous buildup of lactic acid in your bloodstream; symptoms include unexplained muscle pain or weakness, irregular heartbeat and breathing difficulties.
- Immune system changes (Immune Reconstitution Syndrome)
In rare cases with Genvoya:
- Bone problems: fractures due to thinning or softening of bones
- Liver problems: dark-colored urine or yellowing skin
With Descovy:
- Too much fat in your blood (hyperlipidemia): could lead to pancreatitis
- Inflammation of the pancreas
If you experience any aforementioned signs while on either medication, seek immediate medical attention.
What are the most common side effects for Descovy?
Descovy, a popular choice for the treatment of HIV-1 infection in combination with other antiretroviral drugs, may cause some side effects:
- Nausea
- Changes in body fat distribution
- Headache or dizziness
- Abdominal pain and discomfort
- Diarrhea or constipation
- Flatulence (gas)
- Rash or skin discoloration Insomnia or other sleep disorders
It is also important to note that Descovy can sometimes cause serious complications such as lactic acidosis and liver problems. If you experience any unusual symptoms while taking this medication, it's crucial to seek immediate medical attention.
Are there any potential serious side effects for Descovy?
While Descovy is generally well-tolerated, it's important to be aware of potential serious side effects. These can include:
- Signs of allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat
- Liver problems - upper stomach pain, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes)
- Kidney problems - little or no urination; painful or difficult urination; swelling in your feet or ankles; feeling tired
- Lactic acidosis - unusual muscle pain and weakness/numbness; cold feeling in your arms and legs; trouble breathing; nausea with vomiting, fast yet uneven heart rate.
If you experience any of these symptoms while taking Descovy for HIV treatment/prevention purposes immediately seek medical attention.
Contraindications for Genvoya and Descovy?
Both Genvoya and Descovy, along with many other antiretroviral medications, may cause worsening symptoms in some individuals. If you notice any unusual side effects like severe tiredness, persistent nausea or vomiting, yellowing eyes or skin (jaundice), dark urine, stomach/abdominal pain, or pale stools while taking these medicines, please seek immediate medical attention.
Neither Genvoya nor Descovy should be taken if you are using dofetilide (a medication for irregular heartbeat). Always inform your physician about all the medications you are currently taking; drugs like dofetilide will need to be completely cleared from your system to prevent dangerous interactions with both Genvoya and Descovy.
Furthermore, it's important to note that both of these HIV medications can potentially impact kidney function. Regular monitoring of renal health is recommended when using either drug. Both drugs also have potential liver implications particularly for those with Hepatitis B infection - sudden discontinuation may worsen Hepatitis B symptoms.
How much do Genvoya and Descovy cost?
For the brand name versions of these drugs:
- The price for 30 tablets of Genvoya (150/150/200/10 mg) averages around $3,400 which works out to roughly $113/day.
- In comparison, the price for 30 tablets of Descovy (25 mg), used in combination with other antiretroviral treatments, is about $1,800 -- working out to approximately $60/day.
Thus, if you are considering solely based on cost and both options are deemed suitable by your healthcare provider, Descovy could be less expensive on a per-day treatment basis than Genvoya. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
As it stands now there aren't generic versions available for either Genvoya or Descovy due to patent laws protecting their formulations. This means costs remain relatively high compared to many other medications where generics have become available after patents expire.
Popularity of Genvoya and Descovy
Genvoya and Descovy are both used in the treatment of HIV-1 infection.
Genvoya, a brand-name drug which combines four active ingredients, was approved by the FDA in 2015. It is estimated that Genvoya has been prescribed to about 2 million people worldwide since then. In recent years, it has become one of the most commonly-prescribed antiretroviral therapies (ARTs) due to its high level of effectiveness and relatively low risk of side effects.
Descovy, on the other hand, contains two of the same active ingredients as Genvoya but lacks elvitegravir and cobicistat. This makes Descovy a lighter option with fewer potential interactions but also requires it be paired with another antiviral for full effectiveness against HIV-1. Since its approval by the FDA in 2016, Descovy's usage has steadily increased each year; however, it hasn't yet reached Genvoya's popularity levels.
It should be noted that both drugs require careful monitoring due to potential risks associated with their long-term use including bone loss or kidney damage among others.
Conclusion
Both Genvoya and Descovy have a well-established usage in managing HIV infection. They are both highly effective antiretroviral medications, underpinned by numerous clinical studies demonstrating their superiority over placebo treatments. Occasionally, these drugs may be prescribed together depending on the patient's unique health situation; however, this requires careful consideration as they can interact negatively with each other and with other medications.
Genvoya and Descovy work differently in combating HIV: Genvoya is a complete treatment regimen for HIV-1 that contains four active ingredients (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide), while Descovy (emtricitabine/tenofovir alafenamide) is used either alone or combined with other antiretroviral agents to treat HIV-1.
While there is no generic form of these two drugs available currently which could offer cost savings for patients paying out of pocket - they are generally well-tolerated. Both Genvoya and Descovy require continuous monitoring to ensure optimal results over time.
The side effect profiles between the two medicines are quite similar but differ slightly in certain aspects. While both come with possible kidney and liver complications among others due to long-term use, Genvoya can cause more bone density loss compared to Descovy. Patients should closely monitor their overall health status when starting therapy and seek immediate medical attention if any severe symptoms occur or existing conditions worsen.